Verifi and Verifi Plus Prenatal Tests safely and noninvasively screen for the most common chromosomal aneuploidies as early as 10 weeks gestation using a single maternal blood draw. Verifi offerings provide the latest innovation in sequencing with a fast turnaround time, low failure rate, and accurate results.1
Verifi offers proven superiority to traditional screening methods for the screening of common fetal aneuploidies, with reduced false positive rates (increased specificity) and increased positive predictive values (PPV).1,2 Verifi has the lowest published failure rate in the industry—0.1%.1,3,4 Learn about evaluating test performance metrics for NIPT and view metrics for Verifi.
Physicians can order this Illumina service through our network of partner labs. Samples are processed at our CLIA-certified, CAP-accredited lab within 3-5 days. The physician will receive a report for use in discussing results and next steps with the patient.
The Verifi Prenatal Test is a non-invasive screening option for chromosomes 13, 18, and 21, and fetal sex chromosome aneuploidies in both singleton and twin pregnancies
The Verifi Plus Prenatal Test contains everything in the Verifi Prenatal Test and includes additional panels. It is a non-invasive screening option for standard chromosome aneuploidies, certain microdeletions, and all autosomes. Expanded panels (microdeletions or all autosomes) are optional add-ons for singleton pregnancies.
Verifi Plus screens for more chromosome conditions than Verifi.
Women who decline an invasive procedure in the presence of an abnormal ultrasound.
The verifi® Prenatal Test was developed by, and its performance characteristics were determined by Verinata Health, Inc. (VHI), a wholly owned subsidiary of Illumina, Inc. The VHI laboratory is CAP-accredited and certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. It has not been cleared or approved by the U.S. Food and Drug Administration.